Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Phase II study of 2-methoxyestradiol (2ME2), administered in combination with bevacizumab, in patients (Pts) with advanced carcinoid tumors

Phase II study of 2-methoxyestradiol (2ME2), administered in combination with bevacizumab, in patients (Pts) with advanced carcinoid tumors. Gastrointestinal Cancer Sympsosium. 2008.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.